STEPHEN DRESKIN, MD
Osteopathic Medicine at 16 Ave, Denver, CO
License number
Colorado 29367
Category
Osteopathic Medicine
Type
Clinical & Laboratory Immunology
Address
Address
12605 E 16Th Ave, Denver, CO 80045
Phone
(720) 848-0000
(303) 493-7000
(303) 493-7000
Personal information
See more information about STEPHEN DRESKIN at radaris.comName
Address
Phone
1936 S Williams St, Denver, CO 80210
2242 S Ogden St, Denver, CO 80210
935 S Race St, Denver, CO 80209
935 Race St, Denver, CO 80209
998 Pearl St, Denver, CO 80209
Organization information
See more information about STEPHEN DRESKIN at bizstanding.comStephen Dreskin MD,PHD,FAAAAI
1635 Aurora Ct, Aurora, CO 80045
Industry:
Allergist, Internist
Site:
Phone:
(720) 848-1940 (Phone)
Stephen Charles Dreskin
Professional information
Dr. Stephen C Dreskin, Aurora CO - MD (Doctor of Medicine)
Specialties:
Diagnostic Laboratory & Dermatologic Immunology
Address:
1635 Aurora Ct, Aurora 80045
(720) 848-1940 (Phone)
(720) 848-1940 (Phone)
Certifications:
Allergy & Immunology, 1983, Diagnostic Laboratory Immunology, 1990, Internal Medicine, 1980
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
1635 Aurora Ct, Aurora 80045
University of Colorado Hospital - Anschutz Inpatient Pavilion
12605 East 16Th Avenue Dr, Aurora 80045
University of Colorado Hospital - Anschutz Inpatient Pavilion
12605 East 16Th Avenue Dr, Aurora 80045
Philosophy:
Collaborative
Education:
Medical School
Emory University School Of Medicine
Graduated: 1977
University Of California (Davis) Health System Program
National Institutes Of Health Clinical Center Program
Emory University School Of Medicine
Graduated: 1977
University Of California (Davis) Health System Program
National Institutes Of Health Clinical Center Program
Stephen C Dreskin, Aurora CO
Specialties:
Allergist
Address:
12605 E 16Th Ave, Aurora, CO 80045
1635 Aurora Ct, Aurora, CO 80045
1635 Aurora Ct, Aurora, CO 80045
Board certifications:
American Board of Allergy and Immunology Certification in Allergy and Immunology, American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Diagnostic Laboratory Immunology (Internal Medicine)
Professor At University Of Colorado At Denver And Health Sciences Center
Position:
Professor at University of Colorado at Denver and Health Sciences Center
Location:
Greater Denver Area
Industry:
Higher Education
Work:
University of Colorado at Denver and Health Sciences Center
-
Professor
Functional Ige Test Methods And Compositions
US Patent:
2003002, Jan 30, 2003
Filed:
May 29, 2002
Appl. No.:
10/158568
Inventors:
Stephen Dreskin - Denver CO, US
Donald Dibbern - Tigard OR, US
Phillip Williams - Olathe KS, US
Donald Dibbern - Tigard OR, US
Phillip Williams - Olathe KS, US
International Classification:
G01N033/567
US Classification:
435/007210
Abstract:
The present assays provide ex vivo methods for determining a significant and potentially life threatening response of mast cells and/or basophils of a patient to one or more antigens, where the response is mediated by IgE and the Fc RI protein binding and serotonin, histamine or other signaling or mediator of IgE-allergen binding. Cells which express IgE and Fc RI are labeled by uptake of detectable 5-hydroxytryptamine (serotonin) or other signaling compound, and the release of the intracellular pool of detectable compound is triggered by the addition of the allergen to which sensitivity is observed. Significant release in response to a particular compound or composition indicates that there is potentially danger to the patient from whom the cells were prepared if that patient comes in contact with the allergen. The assay can also be manipulated to detect the presence of a potentially dangerous allergen in a composition. Significant release of the detectable signaling compound, especially radiolabeled 5-HT, in response to a composition or compound indicates that there is the potential for a dangerous response to the composition or particular allergen.
Method For Predicting Severity Of Allergic Reaction
US Patent:
2014008, Mar 20, 2014
Filed:
Mar 20, 2012
Appl. No.:
14/006448
Inventors:
Stephen C. Dreskin - Denver CO, US
Kanao Otsu - Denver CO, US
Kanao Otsu - Denver CO, US
Assignee:
The Regents of the University of Colorado, a body corporate - Denver CO
International Classification:
G01N 33/68
US Classification:
506 9, 436501
Abstract:
The present invention provides methods for determining a likelihood of a degree of allergic reaction or a severity thereof using a threshold value rather than the binding activity number between the immunoglobulin of the subject and a test composition comprising a marker protein moiety of the allergy inducing material. In one particular embodiment of the invention, methods are provided for determining a likelihood of a degree of allergic reaction severity of a subject to peanuts using a threshold value of binding between immunoglobulin E (IgE) of the subject and Ara h 2 moiety and Ara h 6 moiety.
Methods For Fructanase And Fructokinase Inhibition
US Patent:
2013019, Aug 1, 2013
Filed:
Nov 27, 2012
Appl. No.:
13/686877
Inventors:
The Regents of the University of Colorado, A Body - Denver CO, US
Miguel A. Lanaspa-Garcia - Denver CO, US
Stephen Dreskin - Denver CO, US
Miguel A. Lanaspa-Garcia - Denver CO, US
Stephen Dreskin - Denver CO, US
Assignee:
The Regents of the University of Colorado, A Body Corporate - Denver CO
International Classification:
A61K 38/14, A61K 45/00
US Classification:
4241581, 514 31
Abstract:
Provided are methods and compositions method for inhibiting fructokinase activity within the gastrointestinal tract cell of a subject. The compositions and methods treat or prevent conditions associated with increased permeability and oxidative stress in the gastrointestinal tract of a subject.